Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.37 on Monday. The stock has a 50 day moving average of $0.39 and a 200-day moving average of $0.71. The firm has a market capitalization of $6.73 million, a PE ratio of -0.06 and a beta of 1.26. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.